Is Aerovate Therapeutics Stock a Good Investment?
Aerovate Therapeutics Investment Advice | AVTE |
- Examine Aerovate Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Aerovate Therapeutics' leadership team and their track record. Good management can help Aerovate Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Aerovate Therapeutics' business and its evolving consumer preferences.
- Compare Aerovate Therapeutics' performance and market position to its competitors. Analyze how Aerovate Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Aerovate Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Aerovate Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Aerovate Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Aerovate Therapeutics is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Good | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Aerovate Therapeutics Stock
Researching Aerovate Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 100.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.95. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aerovate Therapeutics recorded a loss per share of 2.99. The entity had not issued any dividends in recent years.
To determine if Aerovate Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aerovate Therapeutics' research are outlined below:
| Aerovate Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (75.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aerovate Therapeutics currently holds about 151.99 M in cash with (56.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Aerovate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: Shareholder Alert Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders |
Aerovate Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aerovate Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aerovate Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Aerovate Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Aerovate Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-03-30 | 2021-12-31 | -0.31 | -0.35 | -0.04 | 12 | ||
2022-11-14 | 2022-09-30 | -0.5 | -0.56 | -0.06 | 12 | ||
2023-05-15 | 2023-03-31 | -0.6 | -0.67 | -0.07 | 11 | ||
2022-05-16 | 2022-03-31 | -0.28 | -0.45 | -0.17 | 60 | ||
2024-11-14 | 2024-09-30 | -0.17 | -0.56 | -0.39 | 229 | ||
2021-08-16 | 2021-06-30 | -0.16 | -23.8 | -23.64 | 14775 |
Know Aerovate Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aerovate Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aerovate Therapeutics backward and forwards among themselves. Aerovate Therapeutics' institutional investor refers to the entity that pools money to purchase Aerovate Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Octagon Capital Advisors Lp | 2024-09-30 | 465.4 K | Opaleye Management Inc | 2024-09-30 | 440 K | Gsa Capital Partners Llp | 2024-09-30 | 413.8 K | Ikarian Capital, Llc | 2024-09-30 | 368 K | State Street Corp | 2024-06-30 | 341.2 K | Two Sigma Investments Llc | 2024-09-30 | 313.1 K | Geode Capital Management, Llc | 2024-09-30 | 291.9 K | Verition Fund Managegment, Llc | 2024-06-30 | 249 K | Citigroup Inc | 2024-09-30 | 233.4 K | Ra Capital Management, Llc | 2024-09-30 | 9.2 M | Sofinnova Ventures | 2024-06-30 | 3.8 M |
Aerovate Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 76.81 M.Market Cap |
|
Aerovate Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.74) | (0.78) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (0.69) | (0.66) |
Determining Aerovate Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Aerovate Therapeutics is a good buy. For example, gross profit margin measures Aerovate Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aerovate Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Aerovate Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aerovate Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Aerovate Therapeutics' management manipulating its earnings.
Evaluate Aerovate Therapeutics' management efficiency
Aerovate Therapeutics has return on total asset (ROA) of (0.4867) % which means that it has lost $0.4867 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8206) %, meaning that it created substantial loss on money invested by shareholders. Aerovate Therapeutics' management efficiency ratios could be used to measure how well Aerovate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.62. In addition to that, Return On Capital Employed is expected to decline to -0.78. At present, Aerovate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.16 | 2.51 | |
| Tangible Book Value Per Share | 4.16 | 2.51 | |
| Enterprise Value Over EBITDA | (7.05) | (6.70) | |
| Price Book Value Ratio | 5.44 | 5.72 | |
| Enterprise Value Multiple | (7.05) | (6.70) | |
| Price Fair Value | 5.44 | 5.72 | |
| Enterprise Value | 626.2 M | 407.8 M |
Understanding the operational decisions made by Aerovate Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.999 |
Basic technical analysis of Aerovate Stock
As of the 26th of November, Aerovate Therapeutics shows the Risk Adjusted Performance of 0.1393, mean deviation of 2.55, and Downside Deviation of 2.6. Aerovate Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aerovate Therapeutics treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Aerovate Therapeutics is priced correctly, providing market reflects its regular price of 2.68 per share. Please also double-check Aerovate Therapeutics total risk alpha, which is currently at 0.0402 to validate the company can sustain itself at a future point.Aerovate Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aerovate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aerovate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aerovate Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aerovate Therapeutics' Outstanding Corporate Bonds
Aerovate Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aerovate Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aerovate bonds can be classified according to their maturity, which is the date when Aerovate Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Aerovate Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Aerovate Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1393 | |||
| Market Risk Adjusted Performance | 0.6177 | |||
| Mean Deviation | 2.55 | |||
| Semi Deviation | 2.13 | |||
| Downside Deviation | 2.6 | |||
| Coefficient Of Variation | 583.83 | |||
| Standard Deviation | 3.64 | |||
| Variance | 13.22 | |||
| Information Ratio | 0.1353 | |||
| Jensen Alpha | 0.4909 | |||
| Total Risk Alpha | 0.0402 | |||
| Sortino Ratio | 0.1893 | |||
| Treynor Ratio | 0.6077 | |||
| Maximum Drawdown | 19.11 | |||
| Value At Risk | (3.86) | |||
| Potential Upside | 5.58 | |||
| Downside Variance | 6.76 | |||
| Semi Variance | 4.54 | |||
| Expected Short fall | (3.41) | |||
| Skewness | 1.45 | |||
| Kurtosis | 3.8 |
| Risk Adjusted Performance | 0.1393 | |||
| Market Risk Adjusted Performance | 0.6177 | |||
| Mean Deviation | 2.55 | |||
| Semi Deviation | 2.13 | |||
| Downside Deviation | 2.6 | |||
| Coefficient Of Variation | 583.83 | |||
| Standard Deviation | 3.64 | |||
| Variance | 13.22 | |||
| Information Ratio | 0.1353 | |||
| Jensen Alpha | 0.4909 | |||
| Total Risk Alpha | 0.0402 | |||
| Sortino Ratio | 0.1893 | |||
| Treynor Ratio | 0.6077 | |||
| Maximum Drawdown | 19.11 | |||
| Value At Risk | (3.86) | |||
| Potential Upside | 5.58 | |||
| Downside Variance | 6.76 | |||
| Semi Variance | 4.54 | |||
| Expected Short fall | (3.41) | |||
| Skewness | 1.45 | |||
| Kurtosis | 3.8 |
Consider Aerovate Therapeutics' intraday indicators
Aerovate Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aerovate Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 7560.4 | |||
| Daily Balance Of Power | 0.2222 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 2.69 | |||
| Day Typical Price | 2.68 | |||
| Price Action Indicator | 0.005 | |||
| Period Momentum Indicator | 0.02 |
Aerovate Therapeutics Corporate Filings
| 18th of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Aerovate Stock media impact
Far too much social signal, news, headlines, and media speculation about Aerovate Therapeutics that are available to investors today. That information is available publicly through Aerovate media outlets and privately through word of mouth or via Aerovate internal channels. However, regardless of the origin, that massive amount of Aerovate data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aerovate Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aerovate Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aerovate Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aerovate Therapeutics alpha.
Aerovate Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Aerovate Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Aerovate Therapeutics Corporate Management
| Timothy Pigot | VP Commercial | Profile | |
| Sanjeev Khindri | Executive Development | Profile | |
| Benjamin Dake | President, Founder | Profile | |
| Timothy MBA | CEO Director | Profile | |
| Marinus Verwijs | Chief Officer | Profile | |
| Stephen Yu | Senior Quality | Profile | |
| BSc MD | Senior Development | Profile |
Already Invested in Aerovate Therapeutics?
The danger of trading Aerovate Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aerovate Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aerovate Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aerovate Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.99) | Return On Assets (0.49) | Return On Equity (0.82) |
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Aerovate Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.